Cargando…
Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection
Class I- and Class II-restricted epitopes have been identified across the SARS-CoV-2 structural proteome. Vaccine-induced and post-infection SARS-CoV-2 T-cell responses are associated with COVID-19 recovery and protection, but the precise role of T-cell responses remains unclear, and how post-infect...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576055/ https://www.ncbi.nlm.nih.gov/pubmed/36251675 http://dx.doi.org/10.1371/journal.pone.0276241 |
_version_ | 1784811446093217792 |
---|---|
author | Sedegah, Martha Porter, Chad Goguet, Emilie Ganeshan, Harini Belmonte, Maria Huang, Jun Belmonte, Arnel Inoue, Sandra Acheampong, Neda Malloy, Allison M. W. Hollis-Perry, Monique Jackson-Thompson, Belinda Ramsey, Kathy F. Alcorta, Yolanda Maiolatesi, Santina E. Wang, Gregory Reyes, Anatolio E. Illinik, Luca Sanchez-Edwards, Margaret Burgess, Timothy H. Broder, Christopher C. Laing, Eric D. Pollett, Simon D. Villasante, Eileen Mitre, Edward Hollingdale, Michael R. |
author_facet | Sedegah, Martha Porter, Chad Goguet, Emilie Ganeshan, Harini Belmonte, Maria Huang, Jun Belmonte, Arnel Inoue, Sandra Acheampong, Neda Malloy, Allison M. W. Hollis-Perry, Monique Jackson-Thompson, Belinda Ramsey, Kathy F. Alcorta, Yolanda Maiolatesi, Santina E. Wang, Gregory Reyes, Anatolio E. Illinik, Luca Sanchez-Edwards, Margaret Burgess, Timothy H. Broder, Christopher C. Laing, Eric D. Pollett, Simon D. Villasante, Eileen Mitre, Edward Hollingdale, Michael R. |
author_sort | Sedegah, Martha |
collection | PubMed |
description | Class I- and Class II-restricted epitopes have been identified across the SARS-CoV-2 structural proteome. Vaccine-induced and post-infection SARS-CoV-2 T-cell responses are associated with COVID-19 recovery and protection, but the precise role of T-cell responses remains unclear, and how post-infection vaccination (‘hybrid immunity’) further augments this immunity To accomplish these goals, we studied healthy adult healthcare workers who were (a) uninfected and unvaccinated (n = 12), (b) uninfected and vaccinated with Pfizer-BioNTech BNT162b2 vaccine (2 doses n = 177, one dose n = 1) or Moderna mRNA-1273 vaccine (one dose, n = 1), and (c) previously infected with SARS-CoV-2 and vaccinated (BNT162b2, two doses, n = 6, one dose n = 1; mRNA-1273 two doses, n = 1). Infection status was determined by repeated PCR testing of participants. We used FluoroSpot Interferon-gamma (IFN-γ) and Interleukin-2 (IL-2) assays, using subpools of 15-mer peptides covering the S (10 subpools), N (4 subpools) and M (2 subpools) proteins. Responses were expressed as frequencies (percent positive responders) and magnitudes (spot forming cells/10(6) cytokine-producing peripheral blood mononuclear cells [PBMCs]). Almost all vaccinated participants with no prior infection exhibited IFN-γ, IL-2 and IFN-γ+IL2 responses to S glycoprotein subpools (89%, 93% and 27%, respectively) mainly directed to the S2 subunit and were more robust than responses to the N or M subpools. However, in previously infected and vaccinated participants IFN-γ, IL-2 and IFN-γ+IL2 responses to S subpools (100%, 100%, 88%) were substantially higher than vaccinated participants with no prior infection and were broader and directed against nine of the 10 S glycoprotein subpools spanning the S1 and S2 subunits, and all the N and M subpools. 50% of uninfected and unvaccinated individuals had IFN-γ but not IL2 or IFN-γ+IL2 responses against one S and one M subpools that were not increased after vaccination of uninfected or SARS-CoV-2-infected participants. Summed IFN-γ, IL-2, and IFN-γ+IL2 responses to S correlated with IgG responses to the S glycoprotein. These studies demonstrated that vaccinations with BNT162b2 or mRNA-1273 results in T cell-specific responses primarily against epitopes in the S2 subunit of the S glycoprotein, and that individuals that are vaccinated after SARS-CoV-2 infection develop broader and greater T cell responses to S1 and S2 subunits as well as the N and M proteins. |
format | Online Article Text |
id | pubmed-9576055 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-95760552022-10-18 Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection Sedegah, Martha Porter, Chad Goguet, Emilie Ganeshan, Harini Belmonte, Maria Huang, Jun Belmonte, Arnel Inoue, Sandra Acheampong, Neda Malloy, Allison M. W. Hollis-Perry, Monique Jackson-Thompson, Belinda Ramsey, Kathy F. Alcorta, Yolanda Maiolatesi, Santina E. Wang, Gregory Reyes, Anatolio E. Illinik, Luca Sanchez-Edwards, Margaret Burgess, Timothy H. Broder, Christopher C. Laing, Eric D. Pollett, Simon D. Villasante, Eileen Mitre, Edward Hollingdale, Michael R. PLoS One Research Article Class I- and Class II-restricted epitopes have been identified across the SARS-CoV-2 structural proteome. Vaccine-induced and post-infection SARS-CoV-2 T-cell responses are associated with COVID-19 recovery and protection, but the precise role of T-cell responses remains unclear, and how post-infection vaccination (‘hybrid immunity’) further augments this immunity To accomplish these goals, we studied healthy adult healthcare workers who were (a) uninfected and unvaccinated (n = 12), (b) uninfected and vaccinated with Pfizer-BioNTech BNT162b2 vaccine (2 doses n = 177, one dose n = 1) or Moderna mRNA-1273 vaccine (one dose, n = 1), and (c) previously infected with SARS-CoV-2 and vaccinated (BNT162b2, two doses, n = 6, one dose n = 1; mRNA-1273 two doses, n = 1). Infection status was determined by repeated PCR testing of participants. We used FluoroSpot Interferon-gamma (IFN-γ) and Interleukin-2 (IL-2) assays, using subpools of 15-mer peptides covering the S (10 subpools), N (4 subpools) and M (2 subpools) proteins. Responses were expressed as frequencies (percent positive responders) and magnitudes (spot forming cells/10(6) cytokine-producing peripheral blood mononuclear cells [PBMCs]). Almost all vaccinated participants with no prior infection exhibited IFN-γ, IL-2 and IFN-γ+IL2 responses to S glycoprotein subpools (89%, 93% and 27%, respectively) mainly directed to the S2 subunit and were more robust than responses to the N or M subpools. However, in previously infected and vaccinated participants IFN-γ, IL-2 and IFN-γ+IL2 responses to S subpools (100%, 100%, 88%) were substantially higher than vaccinated participants with no prior infection and were broader and directed against nine of the 10 S glycoprotein subpools spanning the S1 and S2 subunits, and all the N and M subpools. 50% of uninfected and unvaccinated individuals had IFN-γ but not IL2 or IFN-γ+IL2 responses against one S and one M subpools that were not increased after vaccination of uninfected or SARS-CoV-2-infected participants. Summed IFN-γ, IL-2, and IFN-γ+IL2 responses to S correlated with IgG responses to the S glycoprotein. These studies demonstrated that vaccinations with BNT162b2 or mRNA-1273 results in T cell-specific responses primarily against epitopes in the S2 subunit of the S glycoprotein, and that individuals that are vaccinated after SARS-CoV-2 infection develop broader and greater T cell responses to S1 and S2 subunits as well as the N and M proteins. Public Library of Science 2022-10-17 /pmc/articles/PMC9576055/ /pubmed/36251675 http://dx.doi.org/10.1371/journal.pone.0276241 Text en https://creativecommons.org/publicdomain/zero/1.0/This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication. |
spellingShingle | Research Article Sedegah, Martha Porter, Chad Goguet, Emilie Ganeshan, Harini Belmonte, Maria Huang, Jun Belmonte, Arnel Inoue, Sandra Acheampong, Neda Malloy, Allison M. W. Hollis-Perry, Monique Jackson-Thompson, Belinda Ramsey, Kathy F. Alcorta, Yolanda Maiolatesi, Santina E. Wang, Gregory Reyes, Anatolio E. Illinik, Luca Sanchez-Edwards, Margaret Burgess, Timothy H. Broder, Christopher C. Laing, Eric D. Pollett, Simon D. Villasante, Eileen Mitre, Edward Hollingdale, Michael R. Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection |
title | Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection |
title_full | Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection |
title_fullStr | Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection |
title_full_unstemmed | Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection |
title_short | Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection |
title_sort | cellular interferon-gamma and interleukin-2 responses to sars-cov-2 structural proteins are broader and higher in those vaccinated after sars-cov-2 infection compared to vaccinees without prior sars-cov-2 infection |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576055/ https://www.ncbi.nlm.nih.gov/pubmed/36251675 http://dx.doi.org/10.1371/journal.pone.0276241 |
work_keys_str_mv | AT sedegahmartha cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT porterchad cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT goguetemilie cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT ganeshanharini cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT belmontemaria cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT huangjun cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT belmontearnel cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT inouesandra cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT acheampongneda cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT malloyallisonmw cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT hollisperrymonique cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT jacksonthompsonbelinda cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT ramseykathyf cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT alcortayolanda cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT maiolatesisantinae cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT wanggregory cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT reyesanatolioe cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT illinikluca cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT sanchezedwardsmargaret cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT burgesstimothyh cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT broderchristopherc cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT laingericd cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT pollettsimond cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT villasanteeileen cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT mitreedward cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection AT hollingdalemichaelr cellularinterferongammaandinterleukin2responsestosarscov2structuralproteinsarebroaderandhigherinthosevaccinatedaftersarscov2infectioncomparedtovaccineeswithoutpriorsarscov2infection |